Department of Bioscience and Bioengineering, Indian Institute of Technology (IIT) Jodhpur, NH 65, Nagaur Road, Karwar, Jodhpur (Rajasthan), India.
Curr Drug Discov Technol. 2020;17(4):515-522. doi: 10.2174/1570163816666190726153441.
Biofilms are consortia of microorganisms encased in extracellular matrix that protect cells from adverse conditions. A biofilm matrix is typically composed of extracellular DNA, cellulose and proteinaceous amyloid fibers. The matrix aids in adhesion to abiotic and biotic surface including medical devices and host tissues. The presence of biofilm makes bacteria more resilient and non-responsive to most current treatment regimes at disposal. Therefore, biofilm-associated infections are serious threat in hospital settings and pose a huge burden on economy. Inhibition of matrix components (cellulose and/or amyloid formation) has emerged as a lucrative alternative strategy to cure biofilm-related infections and combat antibiotic resistance. Here we review the current and emerging therapeutic interventions to mitigate persistent infections due to biofilms. The successful implementation of these interventions will have a huge impact on alleviating the current financial burden on healthcare services.
生物膜是微生物在细胞外基质中形成的联合体，可保护细胞免受不利条件的影响。生物膜基质通常由细胞外 DNA、纤维素和蛋白样淀粉纤维组成。基质有助于微生物黏附在非生物和生物表面，包括医疗器械和宿主组织。生物膜的存在使细菌更具弹性，并且对大多数现有处理方案不敏感。因此，生物膜相关感染是医院环境中的严重威胁，给经济带来了巨大负担。抑制基质成分（纤维素和/或淀粉样形成）已成为治疗生物膜相关感染和对抗抗生素耐药性的一种有前途的替代策略。在这里，我们回顾了目前和新兴的治疗干预措施，以减轻由于生物膜引起的持续感染。这些干预措施的成功实施将对减轻医疗服务当前的经济负担产生巨大影响。
